TY - JOUR
T1 - Bladder outlet obstruction surgery in patients undergoing radiation therapy for prostate cancer
T2 - Adverse events, functional outcomes and quality of life - A scoping review
AU - Vrij, Casper
AU - Heesakkers, John
AU - Van Limbergen, Evert Jan
AU - de Jong, Marc
AU - Bos, Ronald
AU - Oerlemans, Dennis
AU - Bruins, Harman Maxim
AU - Biemold, Nathalie
AU - Marcellissen, Tom
AU - Rademakers, Kevin
AU - de Vries, Peter
AU - Driessen, Elisabeth J. M.
AU - van Osch, Frits
AU - van Roermund, Joep
AU - Hermans, Tom
PY - 2025/3/1
Y1 - 2025/3/1
N2 - Introduction: Lower urinary tract symptoms are common in patients with prostate cancer that undergo radiotherapy. Here, we summarize evidence concerning genitourinary toxicity, lower urinary tract function and quality of life in patients with bladder outlet obstruction prior- and post prostate radiation. Methods: Pubmed, Cochrane and Medline (OVID) were searched for relevant articles concerning genitourinary toxicity, lower urinary tract function and quality of life in patients with prior and post radiation undergoing desobstructive surgery. 529 articles were found, of which 29 were selected. Results: 17 studies reported outcomes in patients undergoing desobstructive surgery before radiotherapy. For urinary adverse events data was inconclusive with some studies suggesting no difference in early or late toxicity (n = 4), while others suggested increased toxicity after desobstruction (n = 4). Studies serially assessing the international prostate symptom score did not find significant differences between baseline and last follow-up for patients with a history of prior transurethral resection of the prostate. 3 studies described favorable outcomes of neo-adjuvant desobstruction in patients undergoing brachytherapy. Although little data is available, bladder outlet obstruction surgery after radiotherapy is associated with high rates of toxicity (such as incontinence). Conclusion: There is insufficient evidence to strongly suggest increased toxicity and/or diminished lower urinary tract function in patients receiving radiotherapy after desobstructive surgery. Furthermore, desobstruction after radiotherapy is unfavorable. Additional research is needed to assess whether neoadjuvant desobstruction is protective against genitourinary toxicity and lower urinary tract dysfunction after radiation therapy.
AB - Introduction: Lower urinary tract symptoms are common in patients with prostate cancer that undergo radiotherapy. Here, we summarize evidence concerning genitourinary toxicity, lower urinary tract function and quality of life in patients with bladder outlet obstruction prior- and post prostate radiation. Methods: Pubmed, Cochrane and Medline (OVID) were searched for relevant articles concerning genitourinary toxicity, lower urinary tract function and quality of life in patients with prior and post radiation undergoing desobstructive surgery. 529 articles were found, of which 29 were selected. Results: 17 studies reported outcomes in patients undergoing desobstructive surgery before radiotherapy. For urinary adverse events data was inconclusive with some studies suggesting no difference in early or late toxicity (n = 4), while others suggested increased toxicity after desobstruction (n = 4). Studies serially assessing the international prostate symptom score did not find significant differences between baseline and last follow-up for patients with a history of prior transurethral resection of the prostate. 3 studies described favorable outcomes of neo-adjuvant desobstruction in patients undergoing brachytherapy. Although little data is available, bladder outlet obstruction surgery after radiotherapy is associated with high rates of toxicity (such as incontinence). Conclusion: There is insufficient evidence to strongly suggest increased toxicity and/or diminished lower urinary tract function in patients receiving radiotherapy after desobstructive surgery. Furthermore, desobstruction after radiotherapy is unfavorable. Additional research is needed to assess whether neoadjuvant desobstruction is protective against genitourinary toxicity and lower urinary tract dysfunction after radiation therapy.
KW - Prostate cancer
KW - Bladder outlet obstruction
KW - Radiotherapy
KW - TURP
KW - URINARY-TRACT SYMPTOMS
KW - BRACHYTHERAPY TRANSURETHRAL RESECTION
KW - PERMANENT IMPLANT BRACHYTHERAPY
KW - PHOTOSELECTIVE VAPORIZATION
KW - GENITOURINARY TOXICITY
KW - RADIOTHERAPY
KW - INCONTINENCE
KW - IMPACT
KW - RISK
U2 - 10.1016/j.cont.2025.101747
DO - 10.1016/j.cont.2025.101747
M3 - (Systematic) Review article
SN - 2772-9737
VL - 13
JO - Continence
JF - Continence
M1 - 101747
ER -